Referencia número: HY-108477

TMPyP4 tosylate

Name: TMPyP4 tosylate
Brand: MedChemExpress
SKU: HY-108477
Price: 25.00 USD
Availability: InStock
Rating: 5 (10 reviews)

(Synonyms: TMP 1363)

10 Cited Publications

Revisión del cliente

Based on 10 publication(s) in Google Scholar

TMPyP4 tosylate (TMP 1363) is a quadruplex-specific ligand. TMPyP4 tosylate inhibits the interaction between G-quadruplexes and IGF-1. TMPyP4 tosylate is a telomerase inhibitor and inhibits cancer cells proliferation. TMPyP4 tosylate is also a stabilizer of nucleic acid secondary structure and an acetylcholinesterase inhibitor. Besides, TMPyP4 tosylate has antiviral activity against SARS-CoV-2.

Para uso exclusivo en investigación. No vendemos a pacientes.

Pureza : 98.0%
No. CAS: 36951-72-1
Fòrmula: C₇₂H₆₆N₈O₁₂S₄
Peso molecular:1363.60

Almacenamiento:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

TMPyP4 tosylate Chemical Structure

No. CAS: 36951-72-1

Tamaño

Precio

Stock

Cantidad

Amount: USD 0.00

* Seleccione Cantidad antes de agregar artículos.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Actividad biológica
- Descripciòn
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (10)
Solvente y solubilidad
- In Vitro
- In Vivo
Protocolo (2)
Pureza y Documentación
Referencias
Help & FAQs
Classifications
Bioz

Actividad biológica

Descripciòn

IC₅₀ & Target

^[2]^[3]^[6]

AChE

G-quadruplex

Telomerase

SARS-CoV-2

Ver todos los productos específicos de isoformas Cholinesterase (ChE) :

AChE
BChE

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	>100 μM Compound: 71	Cytotoxicity against human A549 cells assessed as cell growth inhibition by WST assay Cytotoxicity against human A549 cells assessed as cell growth inhibition by WST assay	[PMID: 35050607]
A549	IC₅₀	0.3 μM Compound: 71	Photodynamic cytotoxicity against human A549 cells assessed as cell growth inhibition upon light irradiation by WST assay Photodynamic cytotoxicity against human A549 cells assessed as cell growth inhibition upon light irradiation by WST assay	[PMID: 35050607]
Bone marrow cell	GI₅₀	16.8 μM Compound: TMPyP4	Antiproliferative activity against human bone marrow cells after 72 hrs by WST-1 assay Antiproliferative activity against human bone marrow cells after 72 hrs by WST-1 assay	[PMID: 27132164]
HeLa	IC₅₀	0.06 μM Compound: 6, TMPyP4	Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction by telomeric repeat amplification protocol	[PMID: 22413845]
HeLa	IC₅₀	0.147 μM Compound: 6, TMPyP4	Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol Inhibition of telomerase in human HeLa cells using 5'-AAT CCG TCG AGC AGA GTT-3' as substrate incubated for 15 mins prior to extension reaction followed by compound washout by spin-telomeric repeat amplification protocol	[PMID: 22413845]
MDA-MB-231	GI₅₀	14.3 μM Compound: TMPyP4	Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by WST-1 assay Antiproliferative activity against human MDA-MB-231 cells after 72 hrs by WST-1 assay	[PMID: 27132164]
MRC5	IC₅₀	>25 μM Compound: TMPyP4	Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay Cytotoxicity against human MRC5 cells assessed as cell growth inhibition after 72 hrs by MTT assay	[PMID: 29323491]
OVCAR-3	GI₅₀	14.6 μM Compound: TMPyP4	Antiproliferative activity against human OVCAR3 cells after 72 hrs by WST-1 assay Antiproliferative activity against human OVCAR3 cells after 72 hrs by WST-1 assay	[PMID: 27132164]
PC-3	GI₅₀	14 μM Compound: TMPyP4	Antiproliferative activity against human PC3 cells after 72 hrs by WST-1 assay Antiproliferative activity against human PC3 cells after 72 hrs by WST-1 assay	[PMID: 27132164]
ScN2a	IC₅₀	130 nM Compound: TMPyP	Inhibition of PrP-res formation in mouse ScN2a cells relative to control Inhibition of PrP-res formation in mouse ScN2a cells relative to control	[PMID: 16987659]

In Vitro

TMPyP4 tosylate (50 µM, 96 h) inhibits telomerase activity in telomerase positive HOS cells^[2].
TMPyP4 tosylate (50 µM, 48 or 96 h) inhibits the growth of HOS cells^[2].
TMPyP4 tosylate (50 µM, 96 h) induces cell apoptosis in HOS, Saos-2, MG-63, and U2OS cell lines^[2].
TMPyP4 tosylate (100 µM, 24 or 48 h) increases cell cycle regulatory proteins and MAPKs in K562 cells^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Viability Assay^[2]

View Protocol

Cell Line:

HOS cells
Concentration:

50 µM
Incubation Time:

48 or 96 h
Result:

Time-dependently inhibited cell viability.

Western Blot Analysis^[4]

View Protocol

Cell Line:

K562 cells
Concentration:

100 µM
Incubation Time:

24 or 48 h
Result:

Increased the expression of p21^CIP1 protein and p57^KIP2 protein.

In Vivo

TMPyP4 tosylate (10 and 20 mg/kg, i.p., two times weekly) inhibits tumor growth in MX-1 tumor model^[5].
TMPyP4 tosylate (15 mg/kg or 30 mg/kg, i.n.) decreases the mean viral loads in SARS-CoV-2-infected hamster^[6].
TMPyP4 tosylate (30 mg/kg, i.n., hamsters) shows a C_max of 17.88 μg/mL at 1 h, and a half-life (T_1/2) of 6.36 h^[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

MX-1 mammary chemoadjuvant model^[5]
Dosage:

10 and 20 mg/kg
Administration:

Intraperitoneal injection (i.p.), twice weekly.
Result:

Inhibited tumor growth and prolonged mice survival.

Animal Model:

SARS-CoV-2-infected hamster^[6]
Dosage:

15 mg/kg or 30 mg/kg
Administration:

i.n., starting at 1 h prior to virus inoculation and continuing until 3 days post infection
Result:

Decreased the mean viral loads in the nasal wash, nasal turbinate and lung tissues.

Chemical Information

No. CAS 36951-72-1
Appearance Solid
Peso molecular 1363.60
Fòrmula C₇₂H₆₆N₈O₁₂S₄
Color Purple to dark purple
SMILES

C[N+]1=CC=C(/C2=C3C=CC(/C(C4=CC=[N+](C)C=C4)=C5C=C/C(N/5)=C(C6=CC=[N+](C)C=C6)/C(C=C/7)=NC7=C(C8=CC=[N+](C)C=C8)/C9=CC=C2N9)=N\3)C=C1.O=S(C%10=CC=C(C)C=C%10)([O-])=O.O=S(C%11=CC=C(C)C=C%11)([O-])=O.O=S(C%12=CC=C(C)C=C%12)([O-])=O.O=S(C%13=CC=C(C)C=C%13)([O-])=O
Synonyms

TMP 1363
Envío

Room temperature in continental US; may vary elsewhere.
Almacenamiento

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (10)

All Bio/Physico-chemical AssayFlow CytometryIn Vivo Efficacy Study

Sort by:

Journal Impact Factor

Nat Commun

Telomeric repeat-containing RNA G-quadruplexes trigger ZBP1-mediated cell death. [Abstract]

2026 Feb 23;17(1):3076. PMID: 41730904
Nat Commun

The G4 resolvase Dhx36 modulates cardiomyocyte differentiation and ventricular conduction system development. [Abstract]

2024 Oct 4;15(1):8602. PMID: 39366945

TMPyP4 tosylate purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Oct 4;15(1):8602. [Abstract]

Luciferase transcriptional activation assays in HeLa cells of promoter regions of Dhx36, Kcne1, Bcl2l11, Ntn1, Ppargc1a (Pgc1a), Fhl2, and Nr4a1 cloned in pGL4.25 luciferase expressing vector. The luciferase activity, measured in Relative light units (R.L.U.) of the different constructs, are shown in the presence or absence of the G4 stabilization drug TMPyP4 tosylate (20 μM; 24 h).
Mol Cell

The MYCN oncoprotein is an RNA-binding accessory factor of the nuclear exosome targeting complex. [Abstract]

2024 Jun 6;84(11):2070-2086.e20. PMID: 38703770
Nucleic Acids Res

RNA G-quadruplexes promote codon repeat-associated ribosomal frameshifting in human genes. [Abstract]

2026 Jan 14;54(2):gkaf1481. PMID: 41543171

TMPyP4 tosylate purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2026 Jan 14;54(2):gkaf1481. [Abstract]

Treatment with TMPyP4 tosylate (2 μM; 26 h) resulted in a 14.18% reduction in the HDAC1 frameshifting ratio in HEK293T cells, whereas the mut1 rG4 mutant exhibited only a minimal reduction (1.88%) compared with the control group.

TMPyP4 tosylate purchased from MedChemExpress. Usage Cited in: Nucleic Acids Res. 2026 Jan 14;54(2):gkaf1481. [Abstract]

The G4-destabilizing porphyrin TMPyP4 tosylate (1-100 μM) induced a concentration-dependent shift in the spectral peak, indicating a transition of the higher order HDAC1 RNA structure to a linear form. Moreover, the high concentration (100 μM) of TMPyP4 disrupted the standard CD spectrum of the G4 structure.
Cell Death Dis

Targeting G-quadruplex by TMPyP4 for inhibition of colorectal cancer through cell cycle arrest and boosting anti-tumor immunity. [Abstract]

2024 Nov 11;15(11):816. PMID: 39528472

TMPyP4 tosylate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Nov 11;15(11):816. [Abstract]

TMPyP4 tosylate (4-8 μM; 48 h) induced a significant increase in apoptosis in CRC cell lines.

TMPyP4 tosylate purchased from MedChemExpress. Usage Cited in: Cell Death Dis. 2024 Nov 11;15(11):816. [Abstract]

TMPyP4 tosylate (30 mg/kg; i.p.; three times a week) markedly decreased tumor weights and volumes of BALB/c nude mice bearing SW620 colorectal tumors.
Int J Biol Macromol

I-motif formation in the promoter region of the B-MYB proto-oncogene. [Abstract]

2025 Mar:296:139582. PMID: 39798757
Anal Chem

Single-Molecule Detection on Intrastrand Interactions among G4 Clusters. [Abstract]

2025 Jun 10;97(22):11617-11626. PMID: 40408126
Microbiol Spectr

Characterization of G-Quadruplexes in Enterovirus A71 Genome and Their Interaction with G-Quadruplex Ligands. [Abstract]

2022 Apr 21;e0046022. PMID: 35446122
Biochemistry

G-Quadruplex-Mediated Transcriptional Regulation of SYT7: Implications for Tumor Progression and Therapeutic Strategies. [Abstract]

2024 Oct 15;63(20):2609-2620. PMID: 39320967
Virology

The UP1 domain is essential for the facilitation effect of HnRNP A1 on PRRSV-2 replication. [Abstract]

2025 Feb:603:110378. PMID: 39731905

Solvente y solubilidad

In Vitro:

DMSO : 10 mg/mL (7.33 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 5 mg/mL (3.67 mM; ultrasonic and warming and heat to 60°C)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.7334 mL

3.6668 mL

7.3335 mL

5 mM

0.1467 mL

0.7334 mL

1.4667 mL

10 mM

---

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Calculadora de molaridad

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculadora de dilución

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 1 mg/mL (0.73 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 1 mg/mL (0.73 mM); Clear solution

This protocol yields a clear solution of ≥ 1 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Working Solution

For the following dissolution methods, please prepare the working solution directly:

It is recommended to prepare fresh solutions and use them promptly within a short period of time.

The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS

Solubility: 7.14 mg/mL (5.24 mM); Clear solution; Need ultrasonic and warming and heat to 60°C

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocolo

All Signal Pathway Related Cell Biology

Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.

Pureza y Documentación

Select Batch:

Pureza: 99.98%

Assay: 99.98%

ee.: 99.98%

Ficha de datos (291 KB)
SDS (394 KB)
- English - EN (394 KB)
- Français - FR (394 KB)
- Deutsch - DE (394 KB)
- Norwegian - NO (394 KB)
- Español - ES (394 KB)
- Swedish - SV (394 KB)
- Italian - IT (394 KB)
- Korean - KR (394 KB)
- Portuguese - PT (394 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instrucciones de manejo (2659 KB)

Referencias

[1]. Chen H, et al. Insuline-like growth factor type I selectively binds to G-quadruplex structures. Biochim Biophys Acta Gen Subj. 2019 Jan;1863(1):31-38. [Content Brief]

[2]. Fujimori J, et al. Antitumor effects of telomerase inhibitor TMPyP4 in osteosarcoma cell lines. J Orthop Res. 2011 Nov;29(11):1707-11. [Content Brief]

[3]. Fujiwara N, et al. a Stabilizer of Nucleic Acid Secondary Structure, Is a Novel Acetylcholinesterase Inhibitor. PLoS One. 2015 Sep 24;10(9):e0139167. [Content Brief]

[4]. Mikami-Terao Y, et al. Antitumor activity of G-quadruplex-interactive agent TMPyP4 in K562 leukemic cells. Cancer Lett. 2008 Mar 18;261(2):226-34. [Content Brief]

[5]. Grand CL, et al. The cationic porphyrin TMPyP4 down-regulates c-MYC and human telomerase reverse transcriptase expression and inhibits tumor growth in vivo. Mol Cancer Ther. 2002 Jun;1(8):565-73. Erratum in: Mol Cancer Ther.2003 Feb;2(2):208. [Content Brief]

[6]. Qin G, et al. RNA G-quadruplex formed in SARS-CoV-2 used for COVID-19 treatment in animal models. Cell Discov. 2022 Sep 6;8(1):86. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
H₂O / DMSO	1 mM	0.7334 mL	3.6668 mL	7.3335 mL	18.3338 mL
DMSO	5 mM	0.1467 mL	0.7334 mL	1.4667 mL	3.6668 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

Bioz

TMPyP4 tosylate

10 Cited Publications

100 mg Obtener un presupuesto

Subscribe to the

MedChemExpress

Newsletter

Nombre del producto:
Referencia número:
Cantidad:
MCE Japan Authorized Agent:

Nombre del producto:
No. CAS:
Species:
Pureza:
Cantidad:

TMPyP4 tosylate

Publications Citing Use of MedChemExpress (MCE) TMPyP4 tosylate

Ver todos los productos específicos de isoformas Cholinesterase (ChE)